Loading data for CTOR — first visit, this takes a few seconds.

Alerte

Citius Oncology Inc. (CTOR)

NasdaqCM: CTOR · Prix en temps réel · USD

0.74

-0.18 (-19.57%)

À la clôture : Aug 19, 2026, 1:06 PM

-19.57% (1D)

Cours acheteur	0.54
Capitalisation boursière	81.91M
Chiffre d’affaires (ttm)	5.61M
Résultat net (ttm)	-42.51M
Bêta	3.49
EPS (ttm)	-0.48
Ratio P/E (ttm)	n/a
P/E prévisionnel	n/a
P/B (ttm)	2.04
P/S (ttm)	14.60
Earnings Date	n/a

Cours vendeur	0.98
Volume	274,784
Volume moy. (20D)	80,365
Ouverture	0.77
Clôture précédente	0.92
Fourchette du jour	0.70 - 0.78
Intervalle de 52 semaines	0.49 - 2.25
Analyste	n/a
Objectif de prix	n/a
Dividendes	n/a
Date ex-dividende	n/a

À propos de CTOR

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc....

[En savoir plus]

Industrie Drug Manufacturers - Specialty & Generic

Secteur Healthcare

Date d’introduction Dec 8, 2022

Employés n/a

Bourse NasdaqCM

Symbole boursier CTOR

Site web https://citiusonc.com/overview/default.aspx

Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de Citius Oncology s’élevait à 0, soit une hausse de undefined% par rapport aux 0 de l’année précédente. Le bénéfice s’élevait à -24.76M, soit une hausse de 17.08%.

États financiers

Surprise sur les résultats

Citius Oncology a publié ses résultats trimestriels le Aug 14, 2026 :

Chiffre d’affaires de $1.67M est inférieur aux estimations de $0, avec Infinity% croissance en glissement annuel.

EPS de -0.08 est inférieur aux estimations de -0.01, avec 0.00% croissance en glissement annuel.

Actualités

2 jours il y a · InvestorsHub

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.

2 mois il y a · Insider Monkey

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, H.C. Wainwright analyst Sway...

3 mois il y a · Pharmaceutical Technology

Citius raises $36.5m for Lymphir commercialisation

The capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m.

4 mois il y a · Simply Wall St.

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. ( NASDAQ:CTOR ) is possibly approaching a major achievement in its business, so we would like to...

5 mois il y a · Insider Monkey

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following...

Page 1 de 2

Citius Oncology Inc. (CTOR)